The most active researchers, institutions, and subtopics in Cholangiocarcinoma, from recent PubMed records. Public authorship only, every figure verifiable by PMID.
Analyzed 600 recent PubMed papers (2021-2026) matching "cholangiocarcinoma targeted treatment". Source: NLM PubMed. Generated July 2026.
| # | Researcher | Affiliation | Papers |
|---|---|---|---|
| 1 | Meric-Bernstam Funda | The University of Texas MD Anderson Cancer Center | 16 |
| 2 | Rimassa Lorenza | Humanitas University | 15 |
| 3 | Lamarca Angela | Fundación Jiménez Díaz University Hospital | 10 |
| 4 | Javle Milind | The University of Texas MD Anderson Cancer Center | 8 |
| 5 | Macarulla Teresa | Vall d'Hebron University Hospital | 8 |
| 6 | Namwat Nisana | Khon Kaen University | 8 |
| 7 | Loilome Watcharin | Khon Kaen University | 8 |
| 8 | Vogel Arndt | Toronto General Hospital | 7 |
| 9 | Zhao Haitao | Peking Union Medical College Hospital | 6 |
| 10 | Casadei-Gardini Andrea | Vita-Salute San Raffaele University | 6 |
| 11 | Zhou Jian | Zhongshan Hospital | 6 |
| 12 | Fan Jia | Zhongshan Hospital | 6 |
| 13 | Bridgewater John | UCL Cancer Institute | 6 |
| 14 | Sitthirak Sirinya | Walailak University | 6 |
| 15 | Wangwiwatsin Arporn | Khon Kaen University | 6 |
| 16 | Klanrit Poramate | Khon Kaen University | 6 |
| 17 | Shen Lin | Peking University Cancer Hospital & Institute | 5 |
| 18 | Zhang Ning | Chinese PLA General Hospital | 5 |
Ranked by recent publication volume; names not yet disambiguated and not citation-weighted. The full brief adds ORCID disambiguation, citation weighting, and clinical-trial investigator data.
METTL1/WDR4 Complex: A Novel Epitranscriptomic Target at the Crossroads of RNA Methylation and Drug Discovery. (2026) · PMID 42473783
Conversion and Neoadjuvant Therapy for Intrahepatic Cholangiocarcinoma: Integrating Precision Medicine to Redefine Surgical Curabi (2026) · PMID 42470704
Predicting Perineural Invasion and Prognosis in Intrahepatic Mass-Forming Cholangiocarcinoma Using DKI and Gadoxetic Acid-Enhanced (2026) · PMID 42469046
Effectiveness and safety of PD-1/PD-L1 inhibitors plus lenvatinib with or without Gemox chemotherapy in advanced intrahepatic chol (2026) · PMID 42464144
Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers. (2026) · PMID 42456173
A full Cholangiocarcinoma brief adds citation weighting, name disambiguation, clinical-trial investigators, and a cited PDF, scoped to your exact molecule, competitor set, or region.